• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Invivyd, Inc. - Common Stock (NQ: IVVD )

    0.9606 +0.0106 (+1.12%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 184,921
    Open 0.9350
    Bid (Size) 0.9300 (3)
    Ask (Size) 1.020 (10)
    Prev. Close 0.9500
    Today's Range 0.9219 - 0.9697
    52wk Range 0.8116 - 5.195
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
    From Invivyd
    Via GlobeNewswire
    Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)
    From Invivyd
    Via GlobeNewswire

    Performance

    YTD
    -73.68%
    -73.68%
    1 Month
    +12.77%
    +12.77%
    3 Month
    -12.67%
    -12.67%
    6 Month
    -75.56%
    -75.56%
    1 Year
    -41.78%
    -41.78%

    More News

    Read More
    Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19
    From Invivyd
    Via GlobeNewswire
    IVVD Stock Earnings: Invivyd Meets EPS for Q1 2024
    Via InvestorPlace
    Invivyd to Participate in Upcoming Investor Conferences
    From Invivyd
    Via GlobeNewswire
    Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™
    From Invivyd
    Via GlobeNewswire
    Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest
    From Invivyd
    Via GlobeNewswire
    Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial
    From Invivyd
    Via GlobeNewswire
    Why Keysight Technologies Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    IVVD Stock Earnings: Invivyd Misses EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights
    From Invivyd
    Via GlobeNewswire
    Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights
    From Invivyd
    Via GlobeNewswire
    Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes
    From Invivyd
    Via GlobeNewswire
    Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
    From Invivyd
    Via GlobeNewswire
    Invivyd to Participate at the Jefferies Global Healthcare Conference
    From Invivyd
    Via GlobeNewswire
    Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial
    From Invivyd
    Via GlobeNewswire
    Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
    From Invivyd
    Via GlobeNewswire
    Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)
    From Invivyd
    Via GlobeNewswire
    Invivyd Elects Two New Independent Members to its Board of Directors
    From Invivyd
    Via GlobeNewswire
    Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
    From Invivyd
    Via GlobeNewswire
    Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
    From Invivyd
    Via GlobeNewswire
    Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
    From Invivyd
    Via GlobeNewswire
    Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
    From Invivyd
    Via GlobeNewswire
    Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
    From Invivyd
    Via GlobeNewswire
    Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
    From Invivyd
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.